IL110045A0 - Pharmaceutical compositions containing oligopeptides combating aids and arc and for immune stimulation and certain such novel oligopeptides - Google Patents

Pharmaceutical compositions containing oligopeptides combating aids and arc and for immune stimulation and certain such novel oligopeptides

Info

Publication number
IL110045A0
IL110045A0 IL11004594A IL11004594A IL110045A0 IL 110045 A0 IL110045 A0 IL 110045A0 IL 11004594 A IL11004594 A IL 11004594A IL 11004594 A IL11004594 A IL 11004594A IL 110045 A0 IL110045 A0 IL 110045A0
Authority
IL
Israel
Prior art keywords
oligopeptides
arc
certain
pharmaceutical compositions
compositions containing
Prior art date
Application number
IL11004594A
Other versions
IL110045A (en
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of IL110045A0 publication Critical patent/IL110045A0/en
Publication of IL110045A publication Critical patent/IL110045A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A61K38/105—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Abstract

PCT No. PCT/EP94/01037 Sec. 371 Date Dec. 18, 1995 Sec. 102(e) Date Dec. 18, 1995 PCT Filed Apr. 2, 1994 PCT Pub. No. WO95/00168 PCT Pub. Date Jan. 5, 1995Described are LHRH-antagonistic and bombesin-antagonistic nona- and decapeptides suitable for use in the preparation of a drug for the treatment of AIDS and ARC as well as for use in the preparation of an immunostimulation drug.
IL11004594A 1993-06-18 1994-06-17 Pharmaceutical compositions containing oligopeptides for combating AIDS and ARC and for immune stimulation and certain such novel oligopeptides IL110045A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4320201A DE4320201A1 (en) 1993-06-18 1993-06-18 Use of Cetrorelix and other nona and decapeptides for the manufacture of a medicament for combating AIDS and for growth stimulation

Publications (2)

Publication Number Publication Date
IL110045A0 true IL110045A0 (en) 1994-10-07
IL110045A IL110045A (en) 2000-06-01

Family

ID=6490614

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11004594A IL110045A (en) 1993-06-18 1994-06-17 Pharmaceutical compositions containing oligopeptides for combating AIDS and ARC and for immune stimulation and certain such novel oligopeptides

Country Status (24)

Country Link
US (1) US5985834A (en)
EP (1) EP0703786B1 (en)
JP (1) JPH08511784A (en)
KR (1) KR100352541B1 (en)
CN (1) CN1136915C (en)
AT (1) ATE213164T1 (en)
AU (1) AU688315B2 (en)
BR (1) BR9406893A (en)
CZ (1) CZ285997B6 (en)
DE (2) DE4320201A1 (en)
DK (1) DK0703786T3 (en)
ES (1) ES2172533T3 (en)
FI (1) FI113008B (en)
HU (1) HUT73673A (en)
IL (1) IL110045A (en)
NO (1) NO320945B1 (en)
PL (1) PL175580B1 (en)
PT (1) PT703786E (en)
RU (1) RU2154492C2 (en)
SG (1) SG52240A1 (en)
TW (1) TW370532B (en)
UA (1) UA41938C2 (en)
WO (1) WO1995000168A1 (en)
ZA (1) ZA944347B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
DE19728737C1 (en) * 1997-07-04 1999-02-11 Johannes Christian Groeninghen Process for the detection and determination of GnRH receptors and the use of GnRH agonists and GnRH antagonists for the treatment of a tumor originating from the brain and / or nervous system and / or the meninges
US8962558B2 (en) 1997-07-04 2015-02-24 Johannes C. van Groeninghen Methods for reducing GnRH-positive tumor cell proliferation using the GnRH antagonist IN3
CN100500692C (en) * 2000-03-14 2009-06-17 赞塔里斯有限公司 Novel LHRH antagonists, preparation method and pharmaceutical use thereof
DE10137174A1 (en) * 2001-07-31 2003-02-13 Zentaris Ag Method of modifying T-cell populations, e.g. for treatment of HIV infection or cancer, comprises administrating luteinizing hormone releasing hormone antagonist at controlled dose insufficient to cause chemical castration
US20040138138A1 (en) * 2001-08-02 2004-07-15 Jurgen Engel Use of LHRH-antagonists in doses that do not cause castration for the improvement of T-cell mediated immunity
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2726247C (en) * 2008-05-29 2018-06-26 Isr Immune System Regulation Ab Method and means for treating viral disease, in particular hiv/aids
EP2682460B1 (en) 2008-07-07 2017-04-26 Oxford Nanopore Technologies Limited Enzyme-pore constructs
CN102144037A (en) 2008-07-07 2011-08-03 牛津纳米孔技术有限公司 Base-detecting pore
GB0820927D0 (en) 2008-11-14 2008-12-24 Isis Innovation Method
CA2750874A1 (en) * 2009-01-30 2010-08-05 Oxford Nanopore Technologies Limited Hybridization linkers
AU2010209528B2 (en) 2009-01-30 2015-10-01 Oxford Nanopore Technologies Limited Adaptors for nucleic acid constructs in transmembrane sequencing
GB0905140D0 (en) 2009-03-25 2009-05-06 Isis Innovation Method
US9751915B2 (en) 2011-02-11 2017-09-05 Oxford Nanopore Technologies Ltd. Mutant pores
IN2014DN00221A (en) 2011-07-25 2015-06-05 Oxford Nanopore Tech Ltd
EP2836506B1 (en) 2012-04-10 2017-04-19 Oxford Nanopore Technologies Limited Mutant lysenin pores
EP2875154B1 (en) 2012-07-19 2017-08-23 Oxford Nanopore Technologies Limited SSB method for characterising a nucleic acid
GB201314695D0 (en) 2013-08-16 2013-10-02 Oxford Nanopore Tech Ltd Method
KR102168813B1 (en) 2013-03-08 2020-10-22 옥스포드 나노포어 테크놀로지즈 리미티드 Enzyme stalling method
GB201313477D0 (en) 2013-07-29 2013-09-11 Univ Leuven Kath Nanopore biosensors for detection of proteins and nucleic acids
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
CN106574300A (en) 2014-05-02 2017-04-19 牛津纳米孔技术公司 Method of improving the movement of a target polynucleotide with respect to a transmembrane pore
US10400014B2 (en) 2014-09-01 2019-09-03 Oxford Nanopore Technologies Ltd. Mutant CsgG pores
US10266885B2 (en) 2014-10-07 2019-04-23 Oxford Nanopore Technologies Ltd. Mutant pores
GB201418159D0 (en) 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
CN105837674A (en) * 2016-03-08 2016-08-10 无限极（中国）有限公司 Bombina orientalis polypeptide, and preparation method and application thereof
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677193A (en) * 1985-02-22 1987-06-30 The Salk Institute For Biological Studies Peptides containing an aliphatic-aromatic ketone side chain
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
AU618029B2 (en) * 1987-11-02 1991-12-12 Imperial Chemical Industries Plc Polypeptide compounds
WO1989009229A1 (en) * 1988-03-31 1989-10-05 Immunobiology Research Institute, Inc. Treatment of hiv viremic patients with thymopentin
HU208439B (en) * 1988-10-14 1993-10-28 Univ Tulane Process for producing pharmaceutical peptides
US5244883A (en) * 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
CH683149A5 (en) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Process for the preparation of microspheres of a biodegradable polymeric material.

Also Published As

Publication number Publication date
PL175580B1 (en) 1999-01-29
HUT73673A (en) 1996-09-30
KR100352541B1 (en) 2002-12-26
IL110045A (en) 2000-06-01
FI956014A (en) 1995-12-14
WO1995000168A1 (en) 1995-01-05
EP0703786A1 (en) 1996-04-03
EP0703786B1 (en) 2002-02-13
UA41938C2 (en) 2001-10-15
FI956014A0 (en) 1995-12-14
BR9406893A (en) 1996-09-10
AU688315B2 (en) 1998-03-12
PL312219A1 (en) 1996-04-01
HU9503605D0 (en) 1996-02-28
NO954996L (en) 1995-12-08
CZ308995A3 (en) 1996-03-13
PT703786E (en) 2002-07-31
DE59410052D1 (en) 2002-03-21
RU2154492C2 (en) 2000-08-20
CZ285997B6 (en) 1999-12-15
NO320945B1 (en) 2006-02-20
NO954996D0 (en) 1995-12-08
FI113008B (en) 2004-02-27
ZA944347B (en) 1995-02-15
TW370532B (en) 1999-09-21
KR960703015A (en) 1996-06-19
JPH08511784A (en) 1996-12-10
SG52240A1 (en) 1998-09-28
AU6564794A (en) 1995-01-17
CN1125400A (en) 1996-06-26
DE4320201A1 (en) 1995-01-12
DK0703786T3 (en) 2002-05-27
ATE213164T1 (en) 2002-02-15
CN1136915C (en) 2004-02-04
ES2172533T3 (en) 2002-10-01
US5985834A (en) 1999-11-16

Similar Documents

Publication Publication Date Title
IL110045A (en) Pharmaceutical compositions containing oligopeptides for combating AIDS and ARC and for immune stimulation and certain such novel oligopeptides
IL111734A0 (en) Compositions for the preparation of in vivo therapeutic products
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
PL340890A1 (en) Adamantane derivatives
IL136369A0 (en) Adamantane derivatives
MY125978A (en) Admantane derivatives
GR3022510T3 (en) Lyospheres comprising gonadotropin
AP9801392A0 (en) Concentrated antibody preparation.
GEP20063741B (en) Nonaryl-Heterocyclic NMDA/NR2B Antagonists
CA2153340A1 (en) Application of riluzole in the treatment of parkinson's desease and parkinsonian syndromes
HK1068606A1 (en) Novel aminobenzoephenones
EP0663835A1 (en) Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy.
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
AU8332791A (en) Oral pharmaceutical compositions containing melatonin
PL315127A1 (en) Deuterised biologically active substances for percutaneous administration
AU9731198A (en) Histogranin peptide and their analgesic use
AU3808795A (en) Water-soluble derivatives of epipodophyllotoxin, process for their preparation, their use as medicinal product and their intended use in anticancer treatments
MXPA02011533A (en) NOVEL FORMULATIONS OF agr; 2, 4 DISULFOPHENYL N TERT BUTYLNITRONE.
AU7941294A (en) Composition for the treatment or prevention of herpes
AU2811400A (en) Stable formulation containing fumagillin
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
UA41326C2 (en) Pharmaceutical composition for prevention or treatment of viral diseases, means for prevention or treatment of viral diseases
AU7533394A (en) Antiacid pharmaceutical composition in the form of a suspension based on sucralphate gel
WO1998050397A3 (en) Chimeric oligonucleotides and the use thereof
MX9706412A (en) Use of inorganic aerogels in pharmacy.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
HP Change in proprietorship
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees